{
    "clinical_study": {
        "@rank": "79121", 
        "arm_group": {
            "arm_group_label": "Omegaven", 
            "arm_group_type": "Other", 
            "description": "No placebo or comparator arm. Only intervention arm with Omegaven."
        }, 
        "brief_summary": {
            "textblock": "This is a clinical study designed to evaluate the safety and benefit of a fish oil based fat\n      emulsion in the treatment of liver disease associated with prolonged use of intravenous\n      nutrition."
        }, 
        "brief_title": "Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Cholestasis", 
        "condition_browse": {
            "mesh_term": "Cholestasis"
        }, 
        "detailed_description": {
            "textblock": "Specific Aims of Study\n\n        1. To determine the safety profile of an intravenous omega-3 fat emulsion (Omegaven\u2122)\n\n        2. To determine if established PN associated liver disease can be reversed or its\n           progression halted by using a parenteral fat emulsion prepared from fish oil as\n           measured by normalization of serum levels of hepatic enzymes and bilirubin."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age < 18 years old\n\n          2. Patients will be PN dependent (unable to meet nutritional needs solely by enteral\n             nutrition) and are expected to require PN for at least another 30 days, may be\n             inpatient or outpatient\n\n          3. Patients considered eligible for study participation must have parenteral nutrition\n             associated liver disease (PNALD) as defined as a direct bilirubin of 2 mg/dl or more.\n             Other causes of liver disease should be excluded. A liver biopsy is not necessary for\n             treatment\n\n          4. Direct bilirubin > 2.0 mg/dl\n\n          5. Signed patient informed consent\n\n          6. The patient must have utilized standard therapies to prevent the progression of\n             his/her liver disease including surgical treatment, cyclic PN, avoiding overfeeding,\n             reduction/removal of copper and manganese from PN, advancement of enteral feeding, or\n             the use of ursodiol (i.e., Actigall\u00ae)\n\n        Exclusion Criteria:\n\n          1. Pregnancy\n\n          2. Other causes of chronic liver disease (Hepatitis C, Cystic fibrosis, biliary atresia,\n             and alpha 1 anti-trypsin deficiency)\n\n          3. Enrollment in any other clinical trial involving an investigational agent (unless\n             approved by the designated physicians on the multidisciplinary team)\n\n          4. The parent or guardian or child unwilling to provide consent or assent\n\n          5. Patients known to be allergic to fish or egg protein and patients with the following\n             contraindications to Omegaven\u2122 use:\n\n               -  Impaired lipid metabolism\n\n               -  Severe hemorrhagic disorders\n\n               -  Unstable diabetes mellitus\n\n               -  Collapse and shock\n\n               -  Stroke/embolism\n\n               -  Recent cardiac infarction\n\n               -  Undefined coma status"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02148146", 
            "org_study_id": "105591"
        }, 
        "intervention": {
            "arm_group_label": "Omegaven", 
            "description": "Fish oil emulsion given 1g/kg/day as infusion", 
            "intervention_name": "Omegaven", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "short bowel syndrome", 
            "intestinal failure", 
            "total parenteral nutrition associated cholestasis"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "contact": {
                    "email": "neojae@ucsd.edu", 
                    "last_name": "Jae Kim, MD PhD", 
                    "phone": "619-543-3759"
                }, 
                "contact_backup": {
                    "email": "rbridge@ucsd.edu", 
                    "last_name": "Renee Bridge, RN", 
                    "phone": "6195433759"
                }, 
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103-8774"
                    }, 
                    "name": "UC San Diego Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jae H Kim, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "akimball@rchsd.org", 
                    "last_name": "Amy Kimball, MD", 
                    "phone": "858-966-4045"
                }, 
                "contact_backup": {
                    "email": "eknodel@rchsd.org", 
                    "last_name": "Ellen Knodel, RT", 
                    "phone": "858-966-4045"
                }, 
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92123"
                    }, 
                    "name": "Rady Children's Hospital of San Diego"
                }, 
                "investigator": {
                    "last_name": "Amy Kimball, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Trial of Omegaven\u2122 Therapy for Parenteral Nutrition Associated Cholestasis", 
        "overall_contact": {
            "email": "neojae@ucsd.edu", 
            "last_name": "Jae Kim, MD PhD", 
            "phone": "6195433759"
        }, 
        "overall_contact_backup": {
            "email": "rbridge@ucsd.edu", 
            "last_name": "Renee Bridge, RN", 
            "phone": "6195433759"
        }, 
        "overall_official": {
            "affiliation": "UC San Diego Medical Center", 
            "last_name": "Jae H Kim, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Duration of elevated direct bilirubin", 
            "safety_issue": "No", 
            "time_frame": "Weekly until direct bilirubin below 2 mg/dL, average treatment for 2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02148146"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, San Diego", 
            "investigator_full_name": "Jae H. Kim", 
            "investigator_title": "Associate Clinical Professor of Pediatrics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of California, San Diego", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of California, San Diego", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}